^
    Back
    Association details:
    Biomarker:TNFRSF18-H
    Cancer:Renal Cell Carcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur Rev Med Pharmacol Sci
    Title:

    Prognostic and predictive significance of GITR in metastatic renal cell carcinoma

    Published date:
    09/05/2023
    Excerpt:
    When patients who received nivolumab in the 2nd line were evaluated, median PFS was found to be 5.7 months in the GITR-low group and 15.7 months in the GITR-high group. Median PFS was statistically significantly higher in the GITR-high group than in the GITR-low group (p=0.026).
    DOI:
    10.26355/eurrev_202308_33433